BIO 2015 Dispatches: Roche Hunts For Assets, Not Companies
This article was originally published in The Pink Sheet Daily
Roche’s strong deal-making position is at least partly due to its acquisition of Genentech, but partnering head Sophie Kornowski-Bonnet explained that the firm is more interested in looking for drugs than bolt-on companies.
You may also be interested in...
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.